Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Zosuquidar (trihydrochloride)

Zosuquidar (LY335979) trihydrochloride is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM) . Zosuquidar trihydrochloride shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research[1][2][3].

Product Specifications

CAS Number

167465-36-3

Product Name Alternative

RS 33295-198 trihydrochloride; LY-335979 trihydrochloride

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

P-glycoprotein

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Zosuquidar-trihydrochloride.html

Purity

99.50

Solubility

DMSO : 1 mg/mL (ultrasonic) |H2O : 5 mg/mL (ultrasonic)

Smiles

FC1([C@H]2[C@@H]1C3=C([C@@H](C4=CC=CC=C42)N5CCN(CC5)C[C@H](COC6=C7C=CC=NC7=CC=C6)O)C=CC=C3)F.Cl.Cl.Cl

Molecular Formula

C32H34Cl3F2N3O2

Molecular Weight

636.99

Precautions

H315, H319, H335

References & Citations

[1]A H Dantzig, et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 1996 Sep 15;56 (18) :4171-9.|[2]Ruoping Tang, et al. Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML) . BMC Cancer. 2008 Feb 13;8:51.|[3]Larry D Cripe, et al. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010 Nov 18;116 (20) :4077-85.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Citation 01

Biochem Biophys Res Commun. 2021 Jun 25:559:222-229.|Biomed Res Int. 2014;2014:850493. |J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 15:1092:72-81.|J Pharm Biomed Anal. 2012 Jul;66:232-9.|Viruses. 2020 Aug 17;12 (8) :901.|Adv Sci (Weinh) . 2025 Aug 4:e04680.|Antiviral Res. 2021 Sep:193:105124.|Biomed Pharmacother. 2020 Sep;129:110506.|Biomed Res Int. 2020 Nov 29;2020:8878158.|bioRxiv. 2024 November 03.|Blood Adv. 2020 Oct 27;4 (20) :5062-5077.|Cancer Cell. 2017 Apr 10;31 (4) :501-515.e8. |Crit Rev Anal Chem. 2022;52 (7) :1557-1571.|Drug Metab Dispos. 2017 May;45 (5) :449-456.|Exp Ther Med. 2021 Feb;21 (2) :128.|Pharmaceutics. 2021 Apr 15;13 (4) :559.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

HHEX Antibody
A24615-100UL 100 µL

HHEX Antibody

Sign In for Pricing
View Details
Pef1 AAV siRNA Pooled Vector
36374164 1.0 µg

Pef1 AAV siRNA Pooled Vector

Sign In for Pricing
View Details
LSP1P2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)
LV732321 1.0 µg DNA

LSP1P2 Lentiviral Vector (Human) (UbC) (pLenti-GIII-UbC)

Sign In for Pricing
View Details
CPSF73 Antibody
DF14066-01 100 µL

CPSF73 Antibody

Sign In for Pricing
View Details
CPSF73 Antibody
DF14066-02 200 µL

CPSF73 Antibody

Sign In for Pricing
View Details
FOXB1 Polyclonal Antibody, HRP Conjugated
bs-11555R-HRP 100 µL

FOXB1 Polyclonal Antibody, HRP Conjugated

Sign In for Pricing
View Details